Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849718 | 0.84 | CA3 (0.52) | ESR1ESR2MAPTHTTLMNA | |
| SCHEMBL8370360 | 0.84 | HSD17B1 (0.64) | ESR1ESR2MAPTHTTLMNA | |
| SCHEMBL13625815 | 0.83 | HMGCR (0.55) | ESR1ESR2MAPTLMNABACE1 | |
| SCHEMBL13652987 | 0.82 | TTR (0.60) | ESR1ESR2MAPTHTTLMNA | |
| SCHEMBL16180578 | 0.82 | ESR1 (0.39) | ESR1ESR2MAPTHTTLMNA | |
| SCHEMBL1616373 | 0.81 | HIF1A (0.54) | MAPTHTTLMNAALOX15HSD17B10 | |
| SCHEMBL4814741 | 0.81 | MAPT (0.47) | MAPTHTTLMNAALOX15MAPK1 | |
| SCHEMBL27884951 | 0.81 | ANO1 (0.43) | ESR1ESR2MAPTHTTLMNA | |
| SCHEMBL12520531 | 0.79 | TYR (0.56) | ESR1ESR2MAPTHTTLMNA | |
| SCHEMBL25782332 | 0.79 | ANO1 (0.45) | MAPTHTTLMNAALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| CN-116655497-B | Amidine derivative compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-06-03 | — | — | CN | disclosed |
| CN-119546580-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4511115-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119019350-A | Novel polycyano structure near infrared fluorescent dye and preparation method and application thereof | 大连理工大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-112996776-B | 6-oxo-1, 6-dihydropyridazine prodrug derivatives, preparation method and application thereof in medicine | 福建盛迪医药有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023160509-A1 | AMIDINE DERIVATIVE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-08-31 | — | — | WO | disclosed |
| CN-116655497-A | Amidine derivative compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-08-29 | — | — | CN | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1675814-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037763-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-0485544-B1 | OXIDATIVE HAIR DYE CONTAINING 3-AMINOPHENOL DERIVATIVES, PROCESS FOR OXIDATIVE DYEING OF HAIR AND NEW 3-AMINOPHENOL DERIVATIVES | WELLA AG (DE) | 1996-10-16 | — | — | EP | disclosed |
| US-5409503-A | High color intensity red shades | WELLA AKTIENGESELLSCHAFT (DE) | 1995-04-25 | — | — | US | disclosed |
| EP-0485544-A1 | OXIDATIVE HAIR DYE CONTAINING 3-AMINOPHENOL DERIVATIVES, PROCESS FOR OXIDATIVE DYEING OF HAIR AND NEW 3-AMINOPHENOL DERIVATIVES. | WELLA AG (DE) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991018583-A1 | OXIDATIVE HAIR DYE CONTAINING 3-AMINOPHENOL DERIVATIVES, PROCESS FOR OXIDATIVE DYEING OF HAIR AND NEW 3-AMINOPHENOL DERIVATIVES | WELLA AKTIENGESELLSCHAFT (DE) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | ESR1 4274/4885ESR2 1620/4885MAPT 4183/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | ESR1 2536/4885ESR2 1493/4885MAPT 3880/4885 |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | PPARA, PPARG, PPARD | ESR1 2728/4885ESR2 1563/4885MAPT 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.